Health experts are questioning the practice of allowing private insurers to manage public Medicaid contracts; doctors and scientists are urging a halt to a taxpayer-funded, $63 million medical trial based in part on the work of prominent Harvard Medical School scientist Piero Anversa; a Michigan pharmacist who refused to refill a woman’s miscarriage medication because he claimed he was a “good Catholic male” is no longer with Meijer.
Health experts are questioning the practice of allowing private insurers to manage public Medicaid contracts, due to a paucity of evidence that these contractors improve patient care or save government money, Kaiser Health News reported. When auditors, lawmakers, and regulators took the time to look, many concluded that Medicaid insurers fail to account for the dollars spent, deliver necessary care, or provide access to a sufficient number of doctors. Some lawmakers have begun to raise alarms even as oversight drags and the number of people covered by these plans continue to grow.Doctors and scientists are urging a halt to a taxpayer-funded, $63 million medical trial based in part on the work of prominent Harvard Medical School scientist Piero Anversa, The Washington Post reported. In the ongoing trial, cardiac stem cells are injected into the hearts of people with heart failure, in the hopes that those cells—alone or in combination with others—will improve patients’ heart function. Anversa’s work has been cast into doubt after Harvard disclosed a years-long investigation had identified “falsified and/or fabricated data” in 31 papers from his laboratory, without specifying which publications were affected. Critics of the study say sick people should not be subjected to the risks of an experiment whose underlying science has been called into question.
A Michigan pharmacist who refused to refill a woman’s miscarriage medication because he claimed he was a “good Catholic male” is no longer with Meijer, The Hill reported. The woman, Rachel Peterson, was prescribed misoprostol following a miscarriage about 11 weeks into her first pregnancy in July. Misoprostol is a drug used in combination with another drug to induce labor, but can also be used against stomach ulcers. The pharmacist told Peterson he did not believe she was having a miscarriage and reportedly refused to transfer it to another pharmacy. She eventually called a different Meijer location 3.5 hours away, where a pharmacist filled the prescription. Peterson filed a complaint through the American Civil Liberties Union of Michigan.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More